Greenway Schond L.
- SEC CIK
- 0001848205
No open-market purchases or sales filed in the past year.
Current role at each company
- DFTX Definium Therapeutics, Inc.Chief Financial Officeras of Mar 26, 2024
- AVTX Avalo Therapeutics, Inc.CFOas of Dec 14, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Greenway Schond L. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
DFTX Definium Therapeutics, Inc.
Chief Financial Officer4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 (view filing) | Dec 26 | Same day | Greenway Schond L.Chief Financial Officer | SSale | −5.65K | $3.63 | −$20.5K | −2.5%216.6K after | |
| Sep 25, 2023 (view filing) | Sep 25 | Same day | Greenway Schond L.Chief Financial Officer | SSale | −5.76K | $3.58 | −$20.6K | −2.5%222.3K after | 2 lots |
| Aug 28, 2023 (view filing) | Aug 25 | 3 days | Greenway Schond L.Chief Financial Officer | SSale | −20.0K | $3.80 | −$76.0K | −8.1%228.0K after | |
| Jun 27, 2023 (view filing) | Jun 27 | Same day | Greenway Schond L.Chief Financial Officer | SSale | −11.6K | $3.20 | −$37.2K | −4.5%248.0K after | 2 lots |
AVTX Avalo Therapeutics, Inc.
CFO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Greenway Schond L.CFO | PPurchase | +2.23K | $1.57 | +$3.50K | +135.0%3.88K after |